[go: up one dir, main page]

MX2023011793A - Inhibidores de poli(adenosin difosfato-ribosa) polimerasa. - Google Patents

Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.

Info

Publication number
MX2023011793A
MX2023011793A MX2023011793A MX2023011793A MX2023011793A MX 2023011793 A MX2023011793 A MX 2023011793A MX 2023011793 A MX2023011793 A MX 2023011793A MX 2023011793 A MX2023011793 A MX 2023011793A MX 2023011793 A MX2023011793 A MX 2023011793A
Authority
MX
Mexico
Prior art keywords
adp
ribose
polymerase
inhibitors
poly
Prior art date
Application number
MX2023011793A
Other languages
English (en)
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Srikant Viswanadha
Debnath Bhuniya
Original Assignee
Rhizen Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Ag filed Critical Rhizen Pharmaceuticals Ag
Publication of MX2023011793A publication Critical patent/MX2023011793A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con inhibidores de poli(ADP-ribosa) polimerasa (PARP) novedosos, métodos para prepararlos, composiciones farmacéuticas que los contienen y a su uso en métodos de tratamiento y/o prevención de enfermedades o trastornos mediados por PARP.
MX2023011793A 2021-04-08 2022-04-07 Inhibidores de poli(adenosin difosfato-ribosa) polimerasa. MX2023011793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141016598 2021-04-08
PCT/IB2022/053282 WO2022215034A1 (en) 2021-04-08 2022-04-07 Inhibitors of poly(adp-ribose) polymerase

Publications (1)

Publication Number Publication Date
MX2023011793A true MX2023011793A (es) 2023-10-12

Family

ID=81940686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011793A MX2023011793A (es) 2021-04-08 2022-04-07 Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.

Country Status (12)

Country Link
US (1) US20240199582A1 (es)
EP (1) EP4320116A1 (es)
JP (1) JP2024515338A (es)
KR (1) KR20240021756A (es)
CN (1) CN117321044A (es)
AU (1) AU2022255809A1 (es)
BR (1) BR112023020615A2 (es)
CA (1) CA3214298A1 (es)
IL (1) IL307339A (es)
MX (1) MX2023011793A (es)
TW (1) TW202304447A (es)
WO (1) WO2022215034A1 (es)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042040A1 (en) 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
NZ525138A (en) 2000-10-30 2004-03-26 Kudos Pharm Ltd Phthalazinone derivatives for use as PARP inhibitors
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
GB2415430B (en) 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PT1660095E (pt) 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
WO2006033003A1 (en) 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2006033007A2 (en) 2004-09-22 2006-03-30 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
GB0428111D0 (en) 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
CN101484421A (zh) 2006-06-15 2009-07-15 库多斯药物有限公司 作为parp抑制剂的2-氧基苯甲酰胺衍生物
WO2007144637A1 (en) 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
EP2035380A2 (en) 2006-06-15 2009-03-18 Kudos Pharmaceuticals Limited Parp inhibitors
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
KR101598231B1 (ko) 2007-10-17 2016-02-26 쿠도스 파마슈티칼스 리미티드 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2ｈ-프탈라진-1-온
JP5745283B2 (ja) 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
CN113209033A (zh) 2014-08-22 2021-08-06 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
WO2016165650A1 (zh) 2015-04-17 2016-10-20 苏州晶云药物科技有限公司 奥拉帕尼与尿素的共晶及其制备方法
US20170204067A1 (en) 2016-01-14 2017-07-20 Scinopharm Taiwan, Ltd. Crystalline forms of olaparib and manufacturing processes therefor
CZ201682A3 (cs) 2016-02-15 2017-08-23 Zentiva, K.S. Solvatované krystalické formy olaparibu, jejich příprava a použití
WO2017153958A1 (en) 2016-03-11 2017-09-14 Lupin Limited Novel polymorphic forms and amorphous form of olaparib
WO2017191562A1 (en) 2016-05-04 2017-11-09 Alembic Pharmaceuticals Limited Process for the preparation of olaparib and polymorphs thereof
EP3504196A4 (en) 2016-08-24 2020-01-22 Scinopharm Taiwan, Ltd. METHOD FOR PRODUCING OLAPARIB
CN108201536A (zh) 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途
CA3096136A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh Rucaparib, talazoparib, veliparib, olaparib and azd 2461 for treating impaired skin wound healing
AU2021262569A1 (en) 2020-04-28 2022-11-24 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors

Also Published As

Publication number Publication date
JP2024515338A (ja) 2024-04-09
US20240199582A1 (en) 2024-06-20
CN117321044A (zh) 2023-12-29
TW202304447A (zh) 2023-02-01
AU2022255809A1 (en) 2023-10-26
BR112023020615A2 (pt) 2023-12-19
EP4320116A1 (en) 2024-02-14
WO2022215034A1 (en) 2022-10-13
CA3214298A1 (en) 2022-10-13
KR20240021756A (ko) 2024-02-19
IL307339A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
NZ784224A (en) Parp1 inhibitors
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
EP4364805A3 (en) Novel pyridazines
WO2016109217A3 (en) Btk inhibitors
EP4520395A3 (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
PH12021550872A1 (en) Therapeutic compounds
ZA202211464B (en) Tetrahydroisoquinoline compounds as nrf2 activators
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
CR20240041A (es) Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con AT2R y/o señalización mediada por AT2R
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021007508A (es) Derivados de oxopiridina sustituidos.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX2022000712A (es) Moduladores de nlrp3.
NZ778223A (en) Modified release tablet formulations containing phosphodiesterase inhibitors
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
PH12022552447A1 (en) Nlrp3 modulators
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
EP4603148A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
MX2023005076A (es) Inhibidores de interleucina-17.
ZA202211465B (en) Tetrahydroisoquinoline compounds as nrf2 activators